Results 101 to 110 of about 12,023 (229)

Giant prolactinoma: case report and review of literature [PDF]

, 2013
“Invasive giant prolactinoma” is a large prolactinoma (>4 cm in dimension) presenting with serum prolactin levels of >1000 ng/dL and mass related clinical symptoms.
Bagher Larijani, Hamidreza Aghaei Meybodi, Masoud Rahmanian, Mohammad-reza Mohajeri-Tehrani   +3 more
core   +2 more sources

Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report

Journal of Medical Case Reports, 2019
Background Prolactinomas are tumors of the pituitary gland that usually respond very well to treatment with cabergoline. Resistance to cabergoline is very rare, but when it occurs, it is a difficult problem to resolve if the tumor is inoperable.
Luiz Augusto Casulari, Lucas Faria de Castro, Iruena Moraes Kessler, José Luiz Mendonça, Maria de Fátima Magalhães Gonzaga   +4 more
doaj   +1 more source

High variability in baseline urinary free cortisol values in patients with Cushing's disease [PDF]

, 2013
Objective Twenty-four-hour urinary free cortisol (UFC) sampling is commonly used to evaluate Cushing's syndrome. Because there are few data on UFC variability in patients with active Cushing's disease, we analysed baseline UFC in a large patient ...
Biller, B. M. K., Colao, A., Findling, J. W., Grp, PBS, Gu, F., Maldonado, M., Newell-Price, J., Petersenn, S., Salgado, L. R., Sen, K.   +9 more
core   +3 more sources

Medical treatment of prolactinomas. [PDF]

, 2011
Prolactinomas, the most prevalent type of neuroendocrine disease, account for approximately 40% of all pituitary adenomas. The most important clinical problems associated with prolactinomas are hypogonadism, infertility and hyposexuality.
A Barlier, A Beckers, A Chattopadhyay, A Ciccarelli, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Di Sarno, A Di Sarno, A Klibanski, A Liuzzi, A Saveanu, A Wakil, A Zárate, AG Lania, AI McCormack, AM Colao, Annamaria Colao, AP Heaney, BM Biller, C Di Somma, C Ferrari, C Rasmussen, C Wang, CY Choong, D Cheung, D Dallabonzana, D McCall, DA De Luis, DA Sisam, DG Johnston, DG Johnston, E Delgrange, E Delgrange, E Delgrange, E Valassi, EJ Lee, F Andersohn, F Bogazzi, F Bogazzi, FF Casanueva, G Raverot, G Schettini, G Zada, GA Kaltsas, HE Turner, I Shimon, I Shimon, J Gorski, J Kharlip, J Schlechte, J Verhelst, J Webster, JC Williams, JJ Orrego, JK Devin, JM Wilson, JP Singh, JS Bevan, JW van't Verlaat, K Thapar, K Thapar, KJ Gräf, L Vilar, LB Nachtigall, LC Tan, LD George, LJ Hofland, M Biswas, M De Rosa, M De Rosa, M De Rosa, M Esteller, M Giusti, M Kars, M Kars, M Lafeber, M Muratori, M Ono, M Rocheville, M Steiger, MC Koppelman, MD Bronstein, ME Molitch, ML Vance, MP Gillam, MP Gillam, MS Huda, N Herring, OM Dekkers, P Fainstein Day, P Lancellotti, P Moriondo, PG Crosignani, PU Freda, R Homburg, R Schade, R Zanettini, RB Rothman, S Cannavò, S Ekeblad, S Karunakaran, S Mohammed, S Vallette, SG Ren, Silvia Savastano, SW Lamberts, SW Lamberts, T Mindermann, T Sabuncu, T Tan, V Goffin, VG Rasmussen, VQ Passos, W Winkelmann, WJ Jeffcoate, WS Maxson, Y Greenman   +131 more
core   +1 more source

Dopamine receptor expression and function in corticotroph pituitary tumors [PDF]

, 2004
The role of dopamine agonist treatment in corticotroph pituitary tumors is controversial. The aim of this study was to evaluate D(2) receptor expression in 20 corticotroph pituitary tumors and to correlate it to the in vitro effect of ...
Annunziato, L., Arvigo, M., Caro, M.L. de, Colao, A. (Annamaria), Ferone, D. (Diego), Herder, W.W. (Wouter) de, Hofland, L.J. (Leo), Kros, J.M. (Johan), Lamberts, S.W.J. (Steven), Lombardi, G. (Gaetano), Pivonello, R. (Rosario)   +10 more
core   +2 more sources

Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline

Indian Journal of Endocrinology and Metabolism, 2016
Introduction: Though hypoadiponectinemia and leptin resistance have been proposed as potential factors for weight gain in patients with hyperprolactinemia (HPL), the effects of HPL and cabergoline on these adipocyte-derived hormones are not clear.
Nazir Ahmad Pala, Bashir Ahmad Laway, Raiz Ahmad Misgar, Zaffar Amin Shah, Tariq A Gojwari, Tariq A Dar   +5 more
doaj   +1 more source

Lesions of pemphigus vulgaris on irradiated skin [PDF]

, 2009
Summary Pemphigus vulgaris (PV) is an autoimmune blistering disease produced by IgG autoantibodies against desmoglein (Dsg)3. Lesions on the skin and mucosa can, in rare cases, be induced by radiotherapy.
Aguado, L. (Leyre), España, A. (Agustín), Marquina, M. (Miren), Pretel, M. (Maider), Ruiz-Carrillo, G. (G.)   +4 more
core   +1 more source

Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation [v1; ref status: indexed, http://f1000r.es/2jm]

F1000Research, 2014
We present a case of a 21 year old male patient diagnosed with a 2.2 cm prolactin-secreting adenoma in contact with the optic chiasm. The patient was treated with up to 6mg/week of cabergoline (total cumulative dose 814 mg) and developed mild ...
Chris G. Yedinak, Shirley McCartney, Troy H. Dillard, Kevin S. Wei, Maria Fleseriu   +4 more
doaj   +1 more source

Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study

, 2022
Robert Krysiak, Karolina Kowalcze, Bogusław Okopień   +2 more
openalex   +1 more source

HKCOG guidelines: induction of ovulation [PDF]

, 2012
This guideline by The Hong Kong College of Obstetricians and Gynaecologists (HKCOG) covers the classification of ovulation disorders, treatment options of various ovulation disorders, and their associated risks ...
Lee, VCY, Li, RHW, Ng, EHY, Yeung, TWY
core